Table 1.

Baseline characteristics of the citations included for analysis.

Studies (Year)[Reference number]	Mean age(years)-GLP1-RA group	Sex (Male/Female)-GLP1-RA group	Total patients (GLP1-RA/control)	Control arm	GLP1-RA arm	Follow up duration
D-LIFT (2020)9	46.6 ± 9.1	23/9	32/32	Standard of care without GLP1-RA	Dulaglutide 0.75 mg/week for 4 weeks, then 1.5 mg/week for 20 weeks	24 weeks
Shao et al. (2014)10	43 ± 4.1	15/15	30/30	Intensive insulin therapy	Exenatide 5 µg BID for 4 weeks, then 10 µg BID for 8 weeks	12 weeks
Liu et al. (2019)11	47.63 ± 10.14	19/16	35/36	Glargine	Exenatide 5 µg BID for 4 weeks, then 10 µg BID for 20 weeks	24 weeks
Dutour et al. (2016)12	51 ± 2	13/9	22/22	Standard of care without GLP1-RA	Exenatide 5 µg BID for 4 weeks, then 10 µg BID for 22 weeks	26 weeks
LEAN (2016)5	50	18/8	26/26	Placebo	Liraglutide 1.8 mg	48 weeks
Tang et al. (2015)13	60.7 ± 16.1	11/7	18/17	Glargine	Liraglutide 1.8 mg	12 weeks
Tian et al. (2018)14	58.5 +  − 7.6	31/21	52/75	Metformin 1 − 1.5 g/day	Liraglutide 0.6—1.8 mg	12 weeks
Newsome et al. (2020)7	54.3 ± 10.2	47/35	82/80	Placebo	Semaglutide 0.4 mg/d	72 weeks